The oral, once-daily Zejula (niraparib) tablet, a first-line and recurrent upkeep care for women with advanced epithelial high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in full or partial remission after platinum-based chemotherapy, has been approved by the Health Sciences Authority, according to a statement from GlaxoSmithKline (GSK) Singapore.
Regardless of whether a patient has a BRCA mutation, Zejula is now the only poly (ADP-ribose) polymerase (PARP) inhibitor licenced in Singapore to be used as a single therapy for patients with advanced and recurrent ovarian cancer.
As of March 2022, Zejula is accessible for the first ovarian cancer (PRIMA) in 44 nations and 2 Special Administration Regions. Zejula is also being tested against a variety of tumour types and in combination with a number of different treatments. Notably, it is now undergoing testing in a Phase III clinical research called ZEST to examine its potential for treating individuals with breast cancers that have the specialised treatment needs of triple-negative breast cancer (TNBC) or BRCAm HER2- breast cancer.
